Various biomarkers are available to support the diagnosis of neurodegenerative diseases in
clinical and research settings. Among the molecular imaging biomarkers, amyloid-PET …

Background Research suggests that measurable change in cerebrospinal fluid (CSF)
biomarkers occurs years in advance of the onset of clinical symptoms (Beckett 2010). In this …

Objective To investigate the relationship between cognitive reserve (CR) and clinical
progression across the Alzheimer disease (AD) spectrum. Methods We selected 839 β …

Alzheimer's disease (AD) is a multifactorial age-related brain disease. Numerous
pathological events run forth in the brain leading to AD. There is an initial long, dormant …

This study was designed to test the interaction between amyloid-β and tau proteins as a
determinant of metabolic decline in preclinical Alzheimer's disease (AD). We assessed 120 …

The aim of this study was to assess the agreement between data on cerebral amyloidosis,
derived using Pittsburgh compound B positron emission tomography and (i) multi-laboratory …

Alzheimer's disease (AD) is characterized by amyloid plaques and tau pathology
(neurofibrillary tangles and neuropil threads). Amyloid plaques are primarily composed of …

Background: Evidence suggests that the concordance between amyloid-PET and
cerebrospinal fluid (CSF) amyloid-ß (Aß) increases when the CSF Aß1–42/Aß1–40 ratio is …

Monoamine oxidase B (MAO-B) has been implicated in the pathogenesis of Alzheimer's
disease (AD) and other neurodegenerative disorders. Increased MAO-B expression in …

Background To enable successful inclusion of electroencephalography (EEG) outcome
measures in Alzheimer's disease (AD) clinical trials, we retrospectively mapped the …